
Sign up to save your podcasts
Or
Alastair and Praveen are joined by Dr. Campbell Rogers, CMO and executive VP at HeartFlow, to discuss the recently-published FORECAST trial. What are the economic and clinical outcomes of selective FFRct use in stable chest pain? Tune in and enjoy!
5
1818 ratings
Alastair and Praveen are joined by Dr. Campbell Rogers, CMO and executive VP at HeartFlow, to discuss the recently-published FORECAST trial. What are the economic and clinical outcomes of selective FFRct use in stable chest pain? Tune in and enjoy!
38,668 Listeners
90,623 Listeners
32,174 Listeners
159 Listeners
865 Listeners
111,294 Listeners
134 Listeners
6,911 Listeners
60 Listeners
34 Listeners